Omeros also has identified MASP-3 as the protein that is critical to the activation of the complement system’s alternative pathway in humans, which is linked to a wide range of immune-related ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...